Downing Ventures, BGF, Mercia, and Calculus Capital backed the Bedfordshire nanotechnology business in its latest round.
"We are delighted to be bringing such high-profile investors on board, who share our ambitious growth plans for the business. This significant investment is a strong endorsement of the MIPs technology, it will enable us to scale our operations and take the business to the next level. MIPs offer many advantages and provide solutions to enable new applications that push the limit of what was previously possible. This investment will enable us to rapidly expand our operations to service these opportunities and bring exciting new products to the market."
The investment round was led by Perwyn, BGF, MMC Ventures and Joe Wicks to support technology expansion and fulfilment capacity.
"We continue to be laser-focused on our vision to become the UK’s most-loved way to eat dinner. This additional investment is not only a validation of our track record, but it is also an endorsement of our strategic vision of the future which is rooted in investing in innovative technology to transform the way we search for, shop for, and cook our food."
The investment from BGF will support the rollout of the metra liver preservation system in the United States.
"This investment is key for 2 reasons. First, the funding will be critical in allowing us to execute our commercial plans in the US. Secondly, having BGF at the board table will ensure we leverage its impressive track record of successfully guiding growing businesses to achieve their full potential. Ultimately this is great news for all our stakeholders including current investors, employees and patients requiring a lifesaving organ transplant."
The round was led by BGF with participation from Parkwalk, Cambridge Enterprise, and Cambridge Innovation Capital.
"Parkwalk are delighted to continue to support the ground breaking technology from Dr Ken Smith’s laboratory at Addenbrookes, which enables the prognosis of IBD and an earlier clinical decision as to the correct drug treatment. This will significantly improve clinical outcomes and enhance patient welfare. The team at PredictImmune have done a magnificent job in productising the technology and are now taking the tests on their commercial pathway. We look forward to seeing the platform extended to benefit clinical outcomes in further diseases."
